Differential increases of specific FMR1 mRNA isoforms in premutation carriers.

Autor:	Pretto DI; Department of Biochemistry and Molecular Medicine, University of California, School of Medicine, Davis, California, USA., Eid JS; Pacific Biosciences, Menlo Park, California, USA., Yrigollen CM; Department of Biochemistry and Molecular Medicine, University of California, School of Medicine, Davis, California, USA., Tang HT; Department of Biochemistry and Molecular Medicine, University of California, School of Medicine, Davis, California, USA., Loomis EW; Department of Biochemistry and Molecular Medicine, University of California, School of Medicine, Davis, California, USA., Raske C; Department of Biochemistry and Molecular Medicine, University of California, School of Medicine, Davis, California, USA., Durbin-Johnson B; Department of Public Health Sciences, University of California Davis, School of Medicine, Davis, California, USA., Hagerman PJ; Department of Biochemistry and Molecular Medicine, University of California, School of Medicine, Davis, California, USA MIND Institute, University of California Davis Medical Center, Sacramento, California, USA., Tassone F; Department of Biochemistry and Molecular Medicine, University of California, School of Medicine, Davis, California, USA MIND Institute, University of California Davis Medical Center, Sacramento, California, USA.
Jazyk:	angličtina
Zdroj:	Journal of medical genetics [J Med Genet] 2015 Jan; Vol. 52 (1), pp. 42-52. Date of Electronic Publication: 2014 Oct 30.
DOI:	10.1136/jmedgenet-2014-102593
Abstrakt:	Background: Over 40% of male and ∼16% of female carriers of a premutation FMR1 allele (55-200 CGG repeats) will develop fragile X-associated tremor/ataxia syndrome, an adult onset neurodegenerative disorder, while about 20% of female carriers will develop fragile X-associated primary ovarian insufficiency. Marked elevation in FMR1 mRNA transcript levels has been observed with premutation alleles, and RNA toxicity due to increased mRNA levels is the leading molecular mechanism proposed for these disorders. However, although the FMR1 gene undergoes alternative splicing, it is unknown whether all or only some of the isoforms are overexpressed in premutation carriers and which isoforms may contribute to the premutation pathology. Methods: To address this question, we have applied a long-read sequencing approach using single-molecule real-time (SMRT) sequencing and qRT-PCR. Results: Our SMRT sequencing analysis performed on peripheral blood mononuclear cells, fibroblasts and brain tissue samples derived from premutation carriers and controls revealed the existence of 16 isoforms of 24 predicted variants. Although the relative abundance of all mRNA isoforms was significantly increased in the premutation group, as expected based on the bulk increase in mRNA levels, there was a disproportionate (fourfold to sixfold) increase, relative to the overall increase in mRNA, in the abundance of isoforms spliced at both exons 12 and 14, specifically Iso10 and Iso10b, containing the complete exon 15 and differing only in splicing in exon 17. Conclusions: These findings suggest that RNA toxicity may arise from a relative increase of all FMR1 mRNA isoforms. Interestingly, the Iso10 and Iso10b mRNA isoforms, lacking the C-terminal functional sites for fragile X mental retardation protein function, are the most increased in premutation carriers relative to normal, suggesting a functional relevance in the pathology of FMR1-associated disorders. (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu